Aligos Therapeutics Inc expected to post a loss of $2.36 a share - Earnings Preview

Aligos Therapeutics

04/08/2025 21:44

Aligos Therapeutics Inc ALGS.OQ ALGS.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

The South San Francisco California-based  company is expected to report a 59.2% decrease in revenue to $433.33 thousand from $1.06 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aligos Therapeutics Inc is for a loss of $2.36 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aligos Therapeutics Inc is $65.00, about 88.5% above its last closing price of $7.46

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-2.74
-2.80
-2.11
Beat
24.6
Dec. 31 2025
-2.50
-3.40
Missed
-36.2
Sep. 30 2024
-2.47
-2.16
-3.07
Missed
-42.3​
Jun. 30 2024
-4.00
-4.00
0.80
Beat
120
​​Mar. 31 2024
-4.75
-4.75
-5.50
Missed
-15.8
Dec. 31 2023
-2.75
-6.75
-5.50
Beat
18.5​
Sep. 30 2023
-11.73
-11.87
-10.25
Beat
13.7
Jun. 30 2023
-12.19
-12.37
-10.75
Beat
13.1

This summary was machine generated August 4 at 20:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)